Lincoln Pharmaceuticals Limited (BOM:531633)

Lincoln Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	326.57	134.14	57.47	50.52	69.34
Short-Term Investments	-	2,085	85.77	77.83	116.57	113.82
Trading Asset Securities	-	-	1,737	1,389	913.26	968.06
Cash & Short-Term Investments	2,412	2,412	1,957	1,524	1,080	1,151
Cash Growth	22.97%	23.24%	28.38%	41.11%	-6.16%	21.81%
Accounts Receivable	-	1,614	1,664	1,618	1,363	1,159
Other Receivables	-	-	1.67	0.64	1.35	3.4
Receivables	-	2,423	2,027	1,922	1,604	1,490
Inventory	-	801.06	786.77	771.68	700.28	727.42
Prepaid Expenses	-	-	18.09	16.25	19.36	3.73
Other Current Assets	-	194.06	210.75	143.83	268.29	156.19
Total Current Assets	-	5,831	4,999	4,378	3,672	3,528
Property, Plant & Equipment	-	1,953	1,860	1,825	1,569	1,476
Long-Term Investments	-	0.03	0.03	0.04	0.03	0.03
Other Intangible Assets	-	9.2	4.4	3.26	2.95	3.83
Other Long-Term Assets	-	42.24	43.07	47.63	33.74	65.15
Total Assets	-	8,904	7,970	7,003	5,874	5,344

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	848.63	849.48	724.4	508.67	716.67
Accrued Expenses	-	-	99.75	90.06	82.92	70.14
Short-Term Debt	-	44.22	-	10.67	19.97	20.44
Current Income Taxes Payable	-	16.55	-	0.71	8.82	42.77
Other Current Liabilities	-	201.05	112.93	96.93	101.08	54.85
Total Current Liabilities	-	1,110	1,062	922.77	721.45	904.86
Long-Term Unearned Revenue	-	64.37	53.85	36.25	47.21	45.39
Pension & Post-Retirement Benefits	-	17.57	7.34	0.97	1.39	-
Long-Term Deferred Tax Liabilities	-	135.34	130.02	114.56	79.41	64.55
Total Liabilities	-	1,328	1,253	1,075	849.46	1,015

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	200.3	200.3	200.3	200.3	200.3
Additional Paid-In Capital	-	-	646.17	646.17	646.17	646.17
Retained Earnings	-	-	5,969	5,182	4,279	3,580
Comprehensive Income & Other	-	7,376	-99.15	-100.06	-100.67	-97.7
Total Common Equity	7,576	7,576	6,717	5,928	5,025	4,329
Shareholders' Equity	7,576	7,576	6,717	5,928	5,025	4,329
Total Liabilities & Equity	-	8,904	7,970	7,003	5,874	5,344

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	44.22	44.22	-	10.67	19.97	20.44
Net Cash (Debt)	2,368	2,368	1,957	1,514	1,060	1,131
Net Cash Growth	20.71%	20.98%	29.28%	42.76%	-6.22%	20.31%
Net Cash Per Share	118.20	118.21	97.71	75.58	52.94	56.46
Filing Date Shares Outstanding	20.03	20.03	20.03	20.03	20.03	20.03
Total Common Shares Outstanding	20.03	20.03	20.03	20.03	20.03	20.03
Working Capital	-	4,720	3,937	3,455	2,951	2,624
Book Value Per Share	378.34	378.34	335.34	295.98	250.86	216.12
Tangible Book Value	7,567	7,567	6,712	5,925	5,022	4,325
Tangible Book Value Per Share	377.88	377.88	335.12	295.82	250.72	215.93
Land	-	-	200.24	200.24	187.36	186.32
Buildings	-	-	626.46	602.21	580.66	478.61
Machinery	-	-	1,675	1,548	1,192	1,031
Construction In Progress	-	-	44.7	34.83	67.14	160.54

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 5, 2026

Data Sources Report a data error